Long-term benefit of Qarziba uncertain, says NICE
The National Institute for Health and Care Excellence has ruled against the provision of NHS funding for EUSA Pharma’s neuroblastoma treatment Qarziba.
4th May 2018
Latest news
Janssen acquires BeneVir Biopharm to advance immunotherapy regimens
BeneVir engineers oncolytic viruses tailored to infect and destroy cancer cells
3rd May 2018
Novartis' biosimilar rituximab delayed in US
Rejection is another win for drugs' originator Roche
3rd May 2018
Merck's MS treatment shows promise in new data
HRA and HRA + DAT patients showed responses to Mavenclad that were generally better than previous outcomes in study population
2nd May 2018
CRUK launches £18m fund for brain tumour research
Brain Tumour Awards aim to help advance understanding about the biology of the disease and the challenges translating discoveries into treatments.
2nd May 2018
Novartis' CAR-T therapy gets second FDA approval
Kymriah approved for treatment of adults with relapsed or refractory large B-cell lymphoma
2nd May 2018
FDA grants Keytruda priority review
If approved by the FDA, this would mark the third indication for Keytruda in metastatic NSCLC in the United States based on OS data
1st May 2018
MRC awards Bristol researcher £1.2M to investigate immune defence against microbes
Research will investigate neutrophil extracellular traps
1st May 2018
FDA approval for Novartis' melanoma combo
Tafinlar/Mekinist combo is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation
1st May 2018
Clinical Researcher of the Year – The Americas: Winners announced!
The winners of the 2018 PharmaTimes Clinical Researcher of the Year competition were announced at an awards ceremony and gala dinner last night. It followed a day of fierce competition at the Regency Hyatt, in which 55 individual finalists and 16 teams battled it out for the coveted pharma in each of their respective categories.
30th April 2018
US priority review for Sanofi, Regeneron’s cemiplimab
US regulators are undertaking a priority review of Sanofi and Regeneron’s cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC), or those with locally advanced CSCC who are not candidates for surgery.
30th April 2018
AZ’ lung cancer drug Tagrisso backed for first-line use
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
30th April 2018
Three medicines step closer to EU approval
Three medicines treating HIV, pain and cancer have been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its latest meeting.
30th April 2018
Final NICE nod for Keytruda in bladder cancer
MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment of bladder cancer, following a final green light from cost regulators.
30th April 2018
